Beta Bionics Insider Sells $10,308 in Stock

Insider Mark Hopman reduces stake in the medical device company

Published on Mar. 4, 2026

Got story updates? Submit your updates here. ›

Beta Bionics, Inc. (NASDAQ:BBNX) insider Mark Hopman sold 834 shares of the company's stock in a transaction on March 2, 2026. The shares were sold at an average price of $12.36, for a total transaction of $10,308.24. Following the sale, Hopman now directly owns 139,486 shares of the company's stock, valued at $1,724,046.96.

Why it matters

Insider transactions can provide insights into a company's performance and future prospects. The sale by Hopman, who previously owned a significant stake, may raise questions about the company's outlook among investors.

The details

Hopman's sale represents a 0.59% decrease in his position. Beta Bionics, a clinical-stage medical device company, is focused on developing automated insulin delivery solutions for people with type 1 diabetes. The company's flagship product is the iLet Bionic Pancreas system, which aims to simplify glycemic control by automatically adjusting insulin dosing.

  • The transaction was disclosed in a document filed with the Securities & Exchange Commission on March 2, 2026.

The players

Mark Hopman

An insider at Beta Bionics, Inc. who sold 834 shares of the company's stock.

Beta Bionics, Inc.

A clinical-stage medical device company focused on developing automated insulin delivery solutions for people with type 1 diabetes.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

This insider sale by a significant shareholder raises questions about the company's outlook and may impact investor sentiment towards Beta Bionics in the near term.